AMPK, now considered as a main therapeutic target in type 2 diabetes [13] and metabolic syndrome [48], is activated not only by the major anti-diabetic agent metformin, but also by polyphenols with antidiabetic potential such as resveratrol [42], epigallocatechinegallate (EGCG) [49] or quercetin [9]. Here, PRKAA2 is linked to metabolic syndrome.